Last reviewed · How we verify
NCT04923802: MOTIVATION
Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
trial in Non-small Cell Lung Cancer in 13 participants. Terminated before completion.
31 December 2021
Quick facts
| Lead sponsor | GeneCast Biotechnology Co., Ltd. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 24 June 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Neoantigen — all drugs for Neoantigen →
- Next-generation Sequencing — all drugs for Next-generation Sequencing →
- Biomarker — all drugs for Biomarker →
Sponsor
GeneCast Biotechnology Co., Ltd.
Who can join
Adults 18 to 75, any sex, with Non-small Cell Lung Cancer or Neoantigen. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multicenter prospective observational and exploratory study aims to develop and validate a novel multi-omics-based computational method for neoantigen prediction in non-small cell lung cancer (NSCLC), and discover biomarkers for evaluation of PD-1/PD-L1 inhibitor's efficacy in patients of advanced NSCLC.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer.
Pan Y, Fu Y, Zeng Y, Liu X, et al · · 2022 · cited 39× · PMID 35255999 · DOI 10.1186/s40364-022-00355-7 -
The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy.
Kye Y, Nagineni L, Gadad S, Ramirez F, et al · · 2022 · cited 7× · PMID 36077792 · DOI 10.3390/cancers14174255
Verify or expand the search:
- PubMed search for NCT04923802
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other GeneCast Biotechnology Co., Ltd. trials
Trials by the same sponsor.
- NCT05668910 — Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA · unknown
- NCT04947995 — Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric Cancer · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04923802 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GeneCast Biotechnology Co., Ltd.
- Last refreshed: 8 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04923802.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing